We describe the term male infant of asymptomatic, healthy nonconsanguineous parents presenting on the first day of life with nonketotic hypoglycemia, seizures, hepatomegaly, cardio-megaly with biventricular hypertrophy, and ventricular arrhythmias. Cranial ultrasound revealed cystic dysplasia with several foci of hyperechogenicity within the right basal ganglia. Free carnitine was markedly decreased in the urine and plasma with a pronounced elevation of plasma long-chain acylcarnitines. Fibroblast carnitine palmitoyltransferase II activity was reduced to 26% and 38% in the father and mother, respectively. The infant expired on day 5 of life from malignant ventricular tachy-arrhythmias. Diffuse lipid accumulation was evident at autopsy, including in the liver, heart, kidney, adrenal cortex, skeletal muscle, and lungs. This new case of infantile CPT-1I deficiency illustrates the severity of the early onset form of CPT-II deficiency.
Get full access to this article
View all access options for this article.
References
1.
1. Roe CR, Coates PM. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed.New York: McGraw-Hill; 1995:1501-1535.
2.
2. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-la-beled substrates in humans. J Clin Invest. 1987;79:359-366.
3.
3. Mersmann HJ, Phinney G. In vitro fatty acid oxidation in liver and heart from neonatal swine. Comp Biochem Physiol B Comp Biochem. 1971;44:219-1350.
4.
4. Ascuitto RJ, Ross-Ascuitto NT, Chen V, Downing SE. Ventricular function and fatty acid metabolism in neonatal piglet heart. Am J Physiol. 1989;256: H9-H15.
5.
5. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395-420.
6.
6. Felig P, Wahren J. Fuel homeostasis in exercise. N Engl J Med. 1975;293:1078-1084.
7.
7. Roe CR, Coates PM. Acyl-CoA dehydrogenase deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 1989;889-914.
8.
8. Hug G, Soukup S, Berry H, Bove K. Carnitine palmitoyltransferase (CPT): deficiency of CPT II but not of CPT I with reduced total and free carnitine but increased acylcarnitine. Pediatr Res. 1989;25:115A-115A (abstract).
9.
9. Elpeleg ON, Joseph A, Branski D, et al. Recurrent metabolic decompensation in profound carnitine palmitoyl-transferase II deficiency. J Pediatr.1993;122:917-919.
10.
10. North KN, Hoppel CL, De Girolami U, et al. Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. J Pediatr.1995;127:414-420.
11.
11. Taroni Ii Verderio E, Fiorucci S, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA. 1992;89:8429-8433.
12.
12. Land JM, Mistry S, Squier W, et al. Neonatal carnitine palmitoyltransferase deficiency: a case with a muscular presentation. In: New Developments in Fatty Acid Oxidation, New York: Wiley-Liss, Inc; 1992:309-315.
13.
13. Vianey-Saban C, Stremler N, Paut O, et al. Infantile form of carnitine palmitoyltransferase II deficiency in a girl with rapid fatalonset. Jlnher Metab Dis. 1995;18:362-363.
14.
14. Elpeleg ON, Gutman A. Profound carnitine palmitoyltransferase II deficiency. J Pediatr.1994;124:159-160 (letter).
15.
15. Zinn AB, Zurcher VL, Kraus F, et al. Carnitine palmitoyl-transferase B (CPT B) deficiency: a heritable cause of neonatal cardiomyopathy and dysgenesis of the kidney. Pediatr Res. 1991;29:73a-73a (abstract).
16.
16. With DR, Theobald M, Santa-Maria M. Carnitine palmitoyltransferase type 2 deficiency: two new cases and successful prenatal diagnosis. Am J Hum Gene. 1991;49:109A-109A (abstract).
17.
17. Demaugre F, Bonnefont J-P, Colonna M, et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. J Clin Invest. 1991;87:859-864.
18.
18. McGarry JD, Foster DW. An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Res. 1976; 17:277-281.
19.
19. Bieber LL, Fiol C. Purification and assay of carnitine acyltransferase. Methods Enzymol1986;123:276-284.
20.
20. Kashfi K, Cook GA. Malonyl-CoA inhibits proteolysis of carnitine palmitoyltransferase. Biochem Biophys Res Commun. 1991;178:600-605.
21.
21. Shapira E, Blitzer MG, Miller JB, Africk DKBiochemical Genetics: A Laboratory Manual. New York: Oxford University Press; 1989:118-118.
22.
22. Verderio E, Cavadini P, Montermini L, Wang H. Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. Hum Mol Genet. 1995;4:19-29.
23.
23. Criddle DN, Dewar GH, Wathey WB, Woodward B. The effects of novel vasodilator long chain acyl carnitine esters in the isolated perfused heart of the rat. Br J Pharmacol. 1990;99:477-480.
24.
24. Sakata K, Hayashi H, Kobayashi A, Yamazaki N. Mechanism of arrhythmias induced by palmitoylcarnitine in guinea pig papillary muscle. Cardiovasc Res. 1989;23:505-511.
25.
25. Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. NEngij Med. 1991;325:1862-1864.
26.
26. Corr PB, Creer MH, Yamada KA, et al. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest. 1989;83: 927-936.
